Paul Friedman MD

Dr. Friedman brings decades of experience in biotechnology and drug discovery, having served in senior leadership roles of several notable biotechnology companies, including CEO of Madrigal Pharmaceuticals; CEO of Incyte; President of R&D at DuPont-Merck Pharmaceutical Company; President of DuPont Pharmaceuticals Research Laboratories; and Senior Vice President of Merck Research Laboratories. Dr. Friedman has served as a board member for several publicly held pharmaceutical companies, including Incyte, from 2001 to 2021, and Alexion, from 2017 through its acquisition by AstraZeneca in 2021. He is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation, and received his M.D. from Harvard Medical School.